Related references
Note: Only part of the references are listed.Revision of: a phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma
Milan van Meekeren et al.
ACTA ONCOLOGICA (2021)
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose
Kim Westerdijk et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
Mariette Labots et al.
CANCERS (2020)
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle
Imke H. Bartelink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Tumor Microenvironment as A Game Changer in Cancer Radiotherapy
Magdalena Jarosz-Biej et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Abnormal vascularization of soft-tissue sarcomas on conventional MRI: Diagnostic and prognostic values
Pauline Ledoux et al.
EUROPEAN JOURNAL OF RADIOLOGY (2019)
Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Ruben S. A. Goedegebuure et al.
FRONTIERS IN IMMUNOLOGY (2019)
Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS
Remy B. Verheijen et al.
THERAPEUTIC DRUG MONITORING (2018)
Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
Szilvia Torok et al.
THERANOSTICS (2017)
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
R. B. Verheijen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Claire Viallard et al.
ANGIOGENESIS (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
Remy B. Verheijen et al.
CLINICAL PHARMACOKINETICS (2017)
Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry
Maikel Herbrink et al.
THERAPEUTIC DRUG MONITORING (2016)
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities
Rick L. M. Haas et al.
ACTA ONCOLOGICA (2015)
Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy
Nienke A. G. Lankheet et al.
CLINICAL LUNG CANCER (2015)
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
A. B. Suttle et al.
BRITISH JOURNAL OF CANCER (2014)
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T. Batchelor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Combining angiogenesis inhibition and radiotherapy: A double-edged sword
Esther A. Kleibeuker et al.
DRUG RESISTANCE UPDATES (2012)
Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia
Shingo Matsumoto et al.
CANCER RESEARCH (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance
Eric B. Haura et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Paul Hamberg et al.
ONCOLOGIST (2010)
A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times
Yanfeng Wang et al.
THERAPEUTIC DRUG MONITORING (2009)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization
Ruud P. M. Dings et al.
CLINICAL CANCER RESEARCH (2007)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II
H Wildiers et al.
BRITISH JOURNAL OF CANCER (2003)
The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma
T Mentzel et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2001)
Share Paper
